at Investor's Business Daily (Jan 20, 2015)
EU antitrust regulators send Johnson & Johnson (JNJ -0.1%) and Novartis (NVS -0.3%) a "statement of objections," or charge sheet, over a "co-promotion" deal they formulated that delayed the release of a generic competitor to J&J's painkiller fentanyl in Holland for 17 months in 2005-2006. The EU can levy fines of up to 10% of annual sales for anti-competitive behavior, although penalties are usually based on the revenues of the product involved. (PR)
How did this change your view of ?
More Bullish More Bearish It Didn't
This impact ()
Thanks for sharing your thoughts.
Submit & View Results
From other sites
at Zacks.com (Jan 20, 2015)
at CNBC.com (Jan 20, 2015)
Pre-Market Earnings Report for January 20, 2015 : JNJ, MS, DAL, HAL, BHI, MTB, RF, IGTE, ATI, EDU, MTG, SAPat Nasdaq.com (Jan 16, 2015)
at CNBC.com (Jan 16, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs